An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety
<p>This review synthesizes the current evidence to assess the efficacy and safety of caplacizumab in the treatment of iTTP, focusing on its impact on TPE requirements, time to platelet normalization, relapse prevention, and treatment-related adverse events. Thirteen studies (11 observational a...
Saved in:
| Main Author: | Mohamed Yassin (4166515) (author) |
|---|---|
| Other Authors: | Rola Ghasoub (16555851) (author), Neda Jafari (22963048) (author), Lulwah Al-Tourah (22963051) (author), Anas Babiker (22963054) (author), Muna AlRasheed (22963057) (author) |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Caplacizumab for pediatric immune thrombotic thrombocytopenic Purpura: A scoping review of current evidence
by: Abdulrahman F. Al-Mashdali (17148316)
Published: (2025) -
Thrombotic and Hypercoagulability Complications of COVID-19: An Update
by: Sapha Shibeeb (7903268)
Published: (2021) -
Acrocyanosis and necrotic purpura
by: Nasser, Selim
Published: (2015) -
Protein prenylation restrains innate immunity by inhibiting Rac1 effector interactions
by: Murali K. Akula (9389280)
Published: (2019) -
Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis
by: Hany A. Zaki (15954222)
Published: (2023)